Document Detail


Interference by antiarrhythmic agents with function of electrical cardiac devices.
MedLine Citation:
PMID:  1730178     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The possible interference of drugs with the function of implanted electrical cardiac devices in two patients is described, and the literature on the interaction between these drugs and devices is reviewed. A 59-year-old woman had a permanent pacemaker implanted after diagnosis of tachycardia-bradycardia syndrome, and her drug regimen of digoxin, verapamil, and warfarin was supplemented with flecainide to prevent paroxysmal atrial fibrillation. A Holter monitor recording performed after five days of flecainide therapy showed the pacemaker was sensing and pacing normally. Approximately three weeks after pacemaker implantation and initiation of flecainide therapy, a Holter monitor recording showed high-grade atrioventricular block and failure of the pacemaker to capture. A chest roentgenogram showed that the pacemaker lead was properly placed. The pacemaker's pulse amplitude and pulse width were increased, and the device again functioned reliably. Six months later the pacing threshold was noted to have returned to normal. A 64-year-old man had a history of aborted sudden cardiac death from ventricular tachyarrhythmias. The patient received an automatic implanted cardioverter-defibrillator (AICD); at that time, a 15-J discharge was required to terminate induced ventricular fibrillation (VF). Three years later, the AICD was replaced; the energy required for VF termination with the new unit was 16 J. Seven months after implantation of the new unit, the patient had several episodes of ventricular tachycardia (VT). Moricizine therapy was initiated. An electrophysiologic study (EPS) three days later showed that a larger shock (28 J) was required to terminate VF and that the pacing threshold had increased.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
D A Tworek; J Nazari; M Ezri; J L Bauman
Related Documents :
3734268 - Automatic burst extrastimulus pacemaker to treat recurrent ventricular tachycardia in a...
8945028 - Evaluation of autosensing as an automatic means of maintaining a 2:1 sensing safety mar...
11990668 - Inhibition of biventricular pacemakers by oversensing of far-field atrial depolarization.
12914618 - Clinical performance of automatic closed-loop stimulation systems.
3899358 - Myocardial metabolic and morphometric changes during canine endotoxin shock before and ...
21247538 - Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to pac...
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Clinical pharmacy     Volume:  11     ISSN:  0278-2677     ISO Abbreviation:  Clin Pharm     Publication Date:  1992 Jan 
Date Detail:
Created Date:  1992-02-19     Completed Date:  1992-02-19     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8207437     Medline TA:  Clin Pharm     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  48-56     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Illinois, College of Pharmacy, Chicago 60612.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Arrhythmia Agents / therapeutic use*
Atrial Fibrillation / prevention & control
Death, Sudden, Cardiac / prevention & control
Digoxin / therapeutic use
Drug Interactions
Electric Countershock*
Female
Flecainide / therapeutic use
Humans
Male
Middle Aged
Pacemaker, Artificial*
Prostheses and Implants*
Verapamil / therapeutic use
Warfarin / therapeutic use
Chemical
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 20830-75-5/Digoxin; 52-53-9/Verapamil; 54143-55-4/Flecainide; 81-81-2/Warfarin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Features and treatment of rabies.
Next Document:  Clinical evaluations of the Wellcolex Colour Shigella and Salmonella tests.